These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1136 related articles for article (PubMed ID: 29740166)

  • 1. Triggering and resolution of inflammation in NASH.
    Schuster S; Cabrera D; Arrese M; Feldstein AE
    Nat Rev Gastroenterol Hepatol; 2018 Jun; 15(6):349-364. PubMed ID: 29740166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and Potential Therapies Targeting Inflammation in NASH.
    Albhaisi S; Noureddin M
    Front Endocrinol (Lausanne); 2021; 12():767314. PubMed ID: 34925237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
    Farrell GC; Haczeyni F; Chitturi S
    Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathways of nonalcoholic fatty liver disease development and progression.
    Bessone F; Razori MV; Roma MG
    Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis.
    Dornas W; Lagente V
    Pharmacol Res; 2019 Mar; 141():418-428. PubMed ID: 30658094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innate Immunity and Inflammation in NAFLD/NASH.
    Arrese M; Cabrera D; Kalergis AM; Feldstein AE
    Dig Dis Sci; 2016 May; 61(5):1294-303. PubMed ID: 26841783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies.
    Luci C; Bourinet M; Leclère PS; Anty R; Gual P
    Front Endocrinol (Lausanne); 2020; 11():597648. PubMed ID: 33384662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Arab JP; Arrese M; Trauner M
    Annu Rev Pathol; 2018 Jan; 13():321-350. PubMed ID: 29414249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.
    Sunny NE; Bril F; Cusi K
    Trends Endocrinol Metab; 2017 Apr; 28(4):250-260. PubMed ID: 27986466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kramer JA; Grindley J; Crowell AM; Makaron L; Kohli R; Kirby M; Mansfield KG; Wachtman LM
    Vet Pathol; 2015 Mar; 52(2):404-13. PubMed ID: 24913270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Aspects in the Pathogenesis of Nonalcoholic Steatohepatitis.
    Gentilini A; Caligiuri A; Provenzano A; Marra F
    Curr Mol Med; 2016; 16(8):710-720. PubMed ID: 27774883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease.
    Zhou L; Shen H; Li X; Wang H
    Front Immunol; 2022; 13():951406. PubMed ID: 35958574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame.
    Ibrahim SH; Hirsova P; Malhi H; Gores GJ
    Dig Dis Sci; 2016 May; 61(5):1325-36. PubMed ID: 26626909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis.
    Wang X; Hausding M; Weng SY; Kim YO; Steven S; Klein T; Daiber A; Schuppan D
    Antioxid Redox Signal; 2018 Jan; 28(2):87-109. PubMed ID: 28635324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.